

# FACULTY BIOGRAPHY



## **Arjang Djamali, MD, MS, FACP, FASN**

*Professor, Medicine*  
Tufts University School of Medicine  
*Chair, Department of Medicine*  
Maine Medical Center  
Portland, ME

**Arjang Djamali, MD, MS, FACP, FASN**, is a professor of medicine at Tufts University School of Medicine and the chair of the Department of Medicine at Maine Medical Center in Portland, ME. He earned his medical degree from Montpellier Medical School in Montpellier, France. He then completed his residency in internal medicine at Wayne State University in Detroit, MI and his fellowship in nephrology at the University of Wisconsin Madison in Madison, WI. Dr Djamali is board certified in internal medicine and nephrology.

Dr Djamali is a member of the American Society of Nephrology, the American Society of Transplantation, the American College of Physicians, and the Association of Professors of Medicine. He is considered a national leader in the areas of antibody-mediated processes and kidney transplant outcomes. Dr Djamali has been funded by the NIH, foundations, and industry throughout his career. He has been a member of the NIH, VA-H, national societies' grant review panels, advisory panels to the FDA and pharmaceutical industry, an invited speaker nationally and internationally, and a member of planning committees for national and international society meetings.

Dr Djamali has published more than 200 manuscripts in peer-reviewed journals and is the associate editor of *Kidney360*, the most recent publication from the American Society of Nephrology.

---

**Stronger for Longer: Managing Chronic Active ABMR in Renal Allograft Recipients**  
**A Care Team Forum®**

# FACULTY BIOGRAPHY



## **Benjamin Adam, MD, FRCPC**

*Laboratory Site Chief and Anatomical Pathology Divisional Director*  
University of Alberta Hospital  
*Associate Professor, Department of Laboratory Medicine and Pathology*  
*Program Director, Renal and Transplantation Pathology Fellowship*  
University of Alberta  
*Medical Lead, North Sector Clinical Trials and Research*  
Alberta Precision Laboratories  
Walter C. Mackenzie Health Sciences Centre  
Edmonton, Alberta, Canada

**Benjamin Adam, MD, FRCPC**, is an anatomical pathologist and associate professor at the University of Alberta, the site chief of Laboratory Medicine, and the divisional director of Anatomical Pathology at the University of Alberta Hospital in Edmonton, Canada. Dr Adam completed his medical school and residency training in anatomical pathology at the University of Alberta, and subspecialty training in renal pathology at Massachusetts General Hospital in Boston, MA, thoracic pathology at Toronto General Hospital in Toronto, ON, and transplantation pathology at the University of Pittsburgh Medical Center in Pittsburgh, PA.

Dr Adam's research is focused on molecular transplantation pathology, including the use of gene expression technologies to diagnose and assess allograft rejection, infection, and injury. He has authored over 45 peer-reviewed journal articles and traveled throughout the world to present and lecture on the topics of his research and clinical expertise.

---

**Stronger for Longer: Managing Chronic Active ABMR in Renal Allograft Recipients**  
**A Care Team Forum®**

# FACULTY BIOGRAPHY



## **Ashley A. Vo, PharmD, FAST**

*Professor, Pediatrics*  
David Geffen School of Medicine at UCLA  
*Director, Transplant Immunotherapy Program*  
Comprehensive Transplant Center  
Cedars-Sinai Medical Center  
Los Angeles, CA

**Ashley A. Vo, PharmD, FAST**, is the administrative director of the Transplant Immunotherapy Program at the Comprehensive Transplant Center at Cedars-Sinai Medical Center and a professor of Pediatrics at the David Geffen School of Medicine at UCLA in Los Angeles, CA. Dr Vo earned her PharmD degree at the University of Southern California in Los Angeles. She then completed a general practice residency and a specialty residency in administration, both at Cedars-Sinai Medical Center.

Dr Vo's research has been in advancing the field of desensitization for the highly HLA sensitized patients awaiting a living donor or deceased donor kidney transplantation. Patients, nationally and internationally, are referred to the Kidney Transplant Immunotherapy Program for desensitization and for transplantation. This program also specializes in ABO-incompatible transplant and in the development of novel therapeutics for the prevention and treatment of antibody-mediated rejection in kidney transplantation.

Dr Vo directs the clinical research group and is a sub-investigator for all kidney transplant investigator-initiated trials and industry sponsored trials. She also serves as an ad hoc reviewer for many journals, including *Transplantation*, *American Journal of Transplantation*, and *Clinical Transplantation* and has published in peer-reviewed journals, including the *New England Journal of Medicine*, *Transplantation*, *American Journal of Transplantation*, *World Journal of Nephrology*, and *Immunotherapy*. Dr Vo has been awarded both the AST Clinician of Distinction Award, a prestigious award that recognizes clinical excellence and creative scholarship to the field of transplantation, and the Fellow of the American Society of Transplant Award.

---

**Stronger for Longer: Managing Chronic Active ABMR in Renal Allograft Recipients**  
**A Care Team Forum®**